Evelo Biosciences

📍 Cambridge, United States🗓 Founded 2015👥 20 employees💰 Last funded 2023
Biotechnology Research🌐 evelobio.com
Website LinkedIn
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Evelo Biosciences?
Evelo Biosciences has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Evelo Biosciences last raise funding?
The most recent investment in Evelo Biosciences recorded on gritt.io was in 2023.
When was Evelo Biosciences founded?
Evelo Biosciences was founded in 2015.
What industry is Evelo Biosciences in?
Evelo Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Evelo Biosciences based?
Evelo Biosciences is headquartered in Cambridge, United States.